These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 30267712)

  • 1. Insights From Antiviral Therapy Into Immune Responses to Hepatitis B and C Virus Infection.
    Rehermann B; Thimme R
    Gastroenterology; 2019 Jan; 156(2):369-383. PubMed ID: 30267712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of innate immunity in HBV infection.
    Han Q; Zhang C; Zhang J; Tian Z
    Semin Immunopathol; 2013 Jan; 35(1):23-38. PubMed ID: 22814721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Host immunity influences disease progression and antiviral efficacy in humans infected with hepatitis B virus.
    Wang FS; Zhang Z
    Expert Rev Gastroenterol Hepatol; 2009 Oct; 3(5):499-512. PubMed ID: 19817672
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Innate and adaptive immune responses in HCV infections.
    Heim MH; Thimme R
    J Hepatol; 2014 Nov; 61(1 Suppl):S14-25. PubMed ID: 25443342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunopathogenesis of Hepatitis B Virus.
    Tseng TC; Huang LR
    J Infect Dis; 2017 Nov; 216(suppl_8):S765-S770. PubMed ID: 29156047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparative review of HLA associations with hepatitis B and C viral infections across global populations.
    Singh R; Kaul R; Kaul A; Khan K
    World J Gastroenterol; 2007 Mar; 13(12):1770-87. PubMed ID: 17465466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contribution of Toll-like receptors to the control of hepatitis B virus infection by initiating antiviral innate responses and promoting specific adaptive immune responses.
    Ma Z; Zhang E; Yang D; Lu M
    Cell Mol Immunol; 2015 May; 12(3):273-82. PubMed ID: 25418467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD8+ T-Cell Responses in Hepatitis B and C: The (HLA-) A, B, and C of Hepatitis B and C.
    Nitschke K; Luxenburger H; Kiraithe MM; Thimme R; Neumann-Haefelin C
    Dig Dis; 2016; 34(4):396-409. PubMed ID: 27170395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HBV Bypasses the Innate Immune Response and Does Not Protect HCV From Antiviral Activity of Interferon.
    Mutz P; Metz P; Lempp FA; Bender S; Qu B; Schöneweis K; Seitz S; Tu T; Restuccia A; Frankish J; Dächert C; Schusser B; Koschny R; Polychronidis G; Schemmer P; Hoffmann K; Baumert TF; Binder M; Urban S; Bartenschlager R
    Gastroenterology; 2018 May; 154(6):1791-1804.e22. PubMed ID: 29410097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Innate Immunity, Inflammation, and Intervention in HBV Infection.
    Yang G; Wan P; Zhang Y; Tan Q; Qudus MS; Yue Z; Luo W; Zhang W; Ouyang J; Li Y; Wu J
    Viruses; 2022 Oct; 14(10):. PubMed ID: 36298831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thymus-derived peptides in the treatment of viral chronic hepatitis.
    Naylor PH; Mutchnick MG
    Dig Dis; 1996; 14(6):362-70. PubMed ID: 9030468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunopathogenesis of HBV Infection.
    Wu J; Han M; Li J; Yang X; Yang D
    Adv Exp Med Biol; 2020; 1179():71-107. PubMed ID: 31741334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Host-virus interactions in hepatitis B and hepatitis C infection.
    Yoshio S; Kanto T
    J Gastroenterol; 2016 May; 51(5):409-20. PubMed ID: 26894594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tickling the TLR7 to cure viral hepatitis.
    Funk E; Kottilil S; Gilliam B; Talwani R
    J Transl Med; 2014 May; 12():129. PubMed ID: 24884741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses.
    Liu CJ; Chuang WL; Lee CM; Yu ML; Lu SN; Wu SS; Liao LY; Chen CL; Kuo HT; Chao YC; Tung SY; Yang SS; Kao JH; Liu CH; Su WW; Lin CL; Jeng YM; Chen PJ; Chen DS
    Gastroenterology; 2009 Feb; 136(2):496-504.e3. PubMed ID: 19084016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review article: novel therapies for hepatitis B virus cure - advances and perspectives.
    Lin CL; Kao JH
    Aliment Pharmacol Ther; 2016 Aug; 44(3):213-22. PubMed ID: 27302653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toll-like receptor-mediated innate immunity orchestrates adaptive immune responses in HBV infection.
    Du Y; Wu J; Liu J; Zheng X; Yang D; Lu M
    Front Immunol; 2022; 13():965018. PubMed ID: 35967443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of Th1 immunity is a common immune mechanism for the successful treatment of hepatitis B and C: tetramer assay and therapeutic implications.
    Tsai SL; Sheen IS; Chien RN; Chu CM; Huang HC; Chuang YL; Lee TH; Liao SK; Lin CL; Kuo GC; Liaw YF
    J Biomed Sci; 2003; 10(1):120-35. PubMed ID: 12566993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The innate immune response to hepatitis B virus infection: implications for pathogenesis and therapy.
    Chang J; Block TM; Guo JT
    Antiviral Res; 2012 Dec; 96(3):405-13. PubMed ID: 23072881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relevance of inapparent coinfection by hepatitis B virus in alpha interferon-treated patients with hepatitis C virus chronic hepatitis.
    Zignego AL; Fontana R; Puliti S; Barbagli S; Monti M; Careccia G; Giannelli F; Giannini C; Buzzelli G; Brunetto MR; Bonino F; Gentilini P
    J Med Virol; 1997 Apr; 51(4):313-8. PubMed ID: 9093946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.